Brief: Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE
11/03/2025 11:19
March 11 (Reuters) - Harrow Inc HROW.O: HARROW EXECUTES FIVE-YEAR STRATEGIC SUPPLY AND DEVELOPMENT AGREEMENT FOR TRIESENCE® HARROW INC - DEVELOPING NEXT-GENERATION TRIESENCE, TARGETING NDA SUBMISSION TO FDA BY END OF 2027 Source text: ID:nBw5TmhqSa Further company coverage: HROW.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates